Evidence map›Paper›PMID 38272857›Full record

ArticleJournal of cachexia, sarcopenia and muscle2024

RORα-GABP-TFAM axis alleviates myosteatosis with fatty atrophy through reinforcement of mitochondrial capacity.

Hyeon-Ji Kim, Sang-Heon Lee, Cheolhee Jeong, Yong-Hyun Han, Mi-Ock Lee

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. EPA and DHA Enhance CACT Promoter Activity by GABP/NRF2.International journal of molecular sciences · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hyeon-Ji KimCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Sang-Heon LeeCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Cheolhee JeongCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Yong-Hyun HanCollege of Pharmacy, Kangwon National University, Chuncheon, South Korea.
Mi-Ock LeeCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Seoul National University · KRKangwon National University · KRNew Generation University College · ET

Funding

Korea Mouse Phenotyping Project NRF-2014M3A9D5A01073556National Research Foundation of Korea 2018R1A5A2024425National Research Foundation of Korea 2021R1A6A3A01088095National Research Foundation of Korea 2022R1A2C2006318
6 · The paper itself

Abstract

backgroundFat infiltration in muscle, called 'myosteatosis', precedes muscle atrophy, which subsequently results in sarcopenia. Myosteatosis is frequently observed in patients with nonalcoholic fatty liver disease (NAFLD). We have previously reported that retinoic acid receptor-related orphan receptor-α (RORα) regulates mitochondrial dynamics and mitophagy in hepatocytes, resulting in an alleviation of NAFLD. In this study, we aimed to investigate the role of RORα in skeletal muscle and to understand molecular mechanisms by which RORα controls mitochondrial capacity, using an NAFLD-associated myosteatosis mouse model.

methodsTo establish a myosteatosis model, 7-week-old C57BL/6N mice were fed with high-fat diet (HFD). After 15 weeks of diet feeding, an adeno-associated virus vector encoding RORα (AAV-RORα) was injected to gastrocnemius (GA) muscles, or after 7 weeks of HFD feeding, JC1-40, an RORα agonistic ligand, was administered daily at a dose of 5 mg/kg/day by oral gavage for 5 weeks. Histological, biochemical and molecular analyses in various in vivo and in vitro experiments were performed.

resultsFirst, the number of oxidative MyHC2a fibres with intensive lipid infiltration increased by 3.8-fold in the red region of the GA of mice with myosteatosis (P < 0.001). RORα was expressed around MyHC2a fibres, and its level increased by 2.7-fold after HFD feeding (P < 0.01). Second, treatment of RORα ligands in C2C12 myoblasts, such as cholesterol sulfate and JC1-40, enhanced the number of oxidative fibres stained for MyHC1 and MyHC2a by two-fold to four-fold (P < 0.01), while it reduced the lipid levels in MyHC2a fibres by 20-50% (P < 0.001) in the presence of palmitic acids. Third, mitochondrial membrane potential (P < 0.01) and total area of mitochondria (P < 0.01) were enhanced by treatment of these ligands. Chromatin immunoprecipitation analysis showed that RORα bound the promoter of GA-binding protein α subunit gene that led to activation of mitochondrial transcription factor A (TFAM) in C2C12 myoblasts (P < 0.05). Finally, intramuscular transduction of AAV-RORα alleviated the HFD-induced myosteatosis with fatty atrophy; lipid contents in MyHC2a fibres decreased by 48% (P < 0.001), whereas the number of MyHC2b fibre increased by 22% (P < 0.001). Also, administration of JC1-40 improved the signs of myosteatosis in that it decreased the level of adipose differentiation-related protein (P < 0.01) but increased mitochondrial proteins such as cytochrome c oxidase 4 and TFAM in GA muscle (P < 0.01).

conclusionsRORα plays a versatile role in regulating the quantity of mitochondria and the oxidative capacity, ultimately leading to an improvement in myosteatosis symptoms.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsAtrophyDNA-Binding ProteinsGA-Binding Protein Transcription FactorHigh Mobility Group ProteinsLipidsMiceMice, Inbred C57BLMitochondriaMitochondrial ProteinsNuclear Receptor Subfamily 1, Group F, Member 1Transcription FactorsDNA-Binding ProteinsGA-Binding Protein Transcription FactorHigh Mobility Group ProteinsLipidsMitochondrial ProteinsNuclear Receptor Subfamily 1, Group F, Member 1Rora protein, mouseTfam protein, mouseTranscription Factorsfatty atrophymitochondrial biogenesismyosteatosisNAFLDRORα

Identifiers

PMID38272857
PMCPMC10995264
OpenAlexW4391238430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.